ASND241220P90000
- 0.00
- 0.000.00%
Ascendis Pharma A/S Newsroom
JPMorgan Updates Its U.S. Analyst Focus List – Adds TPR, ALRM, REG
JPMorgan's 'Analyst Focus List' – Growth, Income, Value, Short Ideas
Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Hold Rating, Maintains Target Price $167
Express News | Ascendis Pharma A/S : Citigroup Cuts Target Price to $200 From $207
A Quick Look at Today's Ratings for Ascendis Pharma A/S(ASND.US), With a Forecast Between $153 to $207
Express News | Acendis Pharma Shares Are Trading Higher After Stifel Maintained a Buy Rating on the Stock and Raised Its Price Target From $200 to $207
European Equities Traded in the US as American Depositary Drop in Friday Trading, Down 2.8% for Week
Ascendis Pharma Price Target Maintained With a $170.00/Share by Cantor Fitzgerald
Oppenheimer Adjusts Ascendis Pharma A/S Price Target to $180 From $190, Maintains Outperform Rating
Ascendis Pharma Is Maintained at Buy by Stifel
Ascendis Pharma Analyst Ratings
Wedbush Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $181
TD Cowen Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Cuts Target Price to $153
Wells Fargo Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $289
Express News | Ascendis Pharma A/S : JP Morgan Cuts Target Price to $165 From $174
Ascendis Pharma A/S (ASND) Q3 2024 Earnings Call Transcript
Express News | Ascendis Sees FY24 Operating Expenses ~€600M
Trending Stocks Today | Domino's Pizza up 7.58% Post-Market
Ascendis Pharma A/S | 6-K: Report of foreign private issuer (related to financial reporting)
Ascendis Pharma Q3 Loss Narrows, Revenue Rises